How effective was barzolvolimab?

In the EMBARQ Phase 3 program for chronic spontaneous urticaria, about 50% of patients on the drug achieved a complete response — total absence of itch and hives — after 24 weeks, versus roughly 15–18% on placebo. One analyst called it the best Phase 3 data set they’d seen.

Why did the stock fall despite good results?

Because of a safety signal: two cases of life-threatening anaphylaxis occurred in one dosed group (one anaphylaxis case also occurred on placebo). Such rare-but-serious events can loom large in a drug’s safety profile and label, so investors reacted.

Celldex characterized the anaphylaxis incidence as “extremely low” among about 2,400 treated patients and maintained a favorable safety profile, and it plans to file for FDA approval next year. The FDA will weigh the full risk-benefit picture.

Celldex’s Barzolvolimab: Strong Hives Data, but Anaphylaxis Spooks Investors

Celldex’s barzolvolimab cleared chronic hives in about half of patients — data one analyst called the best they’d seen — but two anaphylaxis cases sent the shares down and clouded an otherwise strong readout.

A clinical trial can succeed and still spook investors. That’s the story of Celldex Therapeutics, whose experimental drug barzolvolimab posted impressive efficacy against chronic hives — yet saw its shares fall 13% because of a safety signal that overshadowed the good news.

The disease and the drug

Barzolvolimab is being developed for chronic spontaneous urticaria (CSU) — persistent hives that cause relentless itching, burning and swelling for no identifiable trigger, and can be genuinely miserable to live with. The drug represents Celldex’s pivot from oncology into immunology, and analysts have projected peak sales of up to $4.8 billion, making it the company’s central bet.

The strong efficacy

On effectiveness, the data were excellent. In the EMBARQ Phase 3 program, about 50% of patients on barzolvolimab achieved a complete response — a total absence of itch and hives — after 24 weeks, versus roughly 15–18% on placebo. One analyst called it “the best Phase 3 data set we’ve seen across all pivotal studies.” For a disease where many patients aren’t fully controlled by existing options, wiping out symptoms in half of them is a striking result.

The safety signal that spooked the market

So why did the stock drop? Because of two cases of life-threatening anaphylaxis in one of the barzolvolimab-dosed groups. (Notably, one anaphylaxis case also occurred after placebo, complicating the interpretation.) Anaphylaxis — a severe, rapid allergic reaction — is exactly the kind of rare-but-serious event that can loom large in a drug’s safety profile and its eventual label, even when it’s uncommon. Investors, focused on the risk to a multibillion-dollar franchise, reacted before the nuance settled.

The company’s response

Celldex sought to reassure, noting the anaphylaxis incidence was “extremely low” among roughly 2,400 treated patients overall, and maintaining that the drug showed “a favorable safety profile.” CEO Anthony Marucci emphasized the rarity of the events. The company still plans to file for FDA approval next year.

Why it matters

This episode captures a recurring tension in drug development: efficacy and safety are judged together, and even excellent efficacy can be discounted by a serious safety question. Whether barzolvolimab’s anaphylaxis signal proves to be a minor footnote or a meaningful limitation will shape its commercial fate — a decision that ultimately rests with the FDA, which will weigh the full risk-benefit picture. For patients with debilitating chronic hives, the hope is that a highly effective drug can reach them with appropriate safeguards. Business news, not investment or medical advice.

This article is for general information only and is not medical advice. Consult a qualified healthcare professional for any medical decisions.

Strong Results, Shaky Stock: A Hives Drug’s Safety Signal Rattles Investors